Verona Pharma plc (NASDAQ: VRNA) announced the ENHANCE-2 trial, which is testing Ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, has closed patient enrollment with over 800 individuals randomized (COPD). In the third quarter of 2022, top-line data is expected.
Ensifentrine is a first-of-its-kind pharmaceutical candidate that combines bronchodilator and anti-inflammatory properties in a single molecule. As monotherapy or when combined with a maintenance bronchodilator, Ensifentrine has shown substantial and clinically important benefits in lung function, symptoms, and quality of life in previous COPD clinical studies. Ensifentrine has been well endured in over 1,400 participants in clinical trials so far.
Furthermore, the finalization of patient registration in Phase 3 ENHANCE-2 trial with more than 800 subjects is a crucial accomplishment for Verona Pharma. The company is excited to reach its recruitment targets during the ongoing global pandemic. In addition, the company is likely to report top-line data from ENHANCE-2 in the Q3 of 2022 and from ENHANCE-1 around the end of 2022.
Moreover, the Phase 3 ENHANCE study includes two double-blind, placebo-controlled studies (ENHANCE-1 and ENHANCE-2) that look at nebulized Ensifentrine for COPD maintenance. ENHANCE is the acronym of Ensifentrine as a Novel inHAled Nebulized COPD thErapy. In December 2021, the ENHANCE-1 trial's 48-week subgroup concluded recruitment of roughly 400 patients, which was originally disclosed on January 5, 2022.